Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis
Ana F. Castillo, Ulises Orlando, Paula Maloberti, et al.
Cellular and Molecular Life Sciences (2020) Vol. 78, Iss. 6, pp. 2893-2910
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Targeting ferroptosis opens new avenues for the development of novel therapeutics
Shumin Sun, Jie Shen, Jianwei Jiang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 232
Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy
Rui Sha, Yaqian Xu, Chenwei Yuan, et al.
EBioMedicine (2021) Vol. 71, pp. 103560-103560
Open Access | Times Cited: 114
ACSL3 and ACSL4, Distinct Roles in Ferroptosis and Cancers
Yufei Yang, Ting Zhu, Xu Wang, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5896-5896
Open Access | Times Cited: 101
Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism
Kaiyue Ding, Chongbin Liu, Li Li, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 74
The role of lipid metabolic reprogramming in tumor microenvironment
Kai Yang, Xiaokun Wang, Chenghu Song, et al.
Theranostics (2023) Vol. 13, Iss. 6, pp. 1774-1808
Open Access | Times Cited: 67
RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis
Mu‐En Wang, Jiaqi Chen, Yi Lu, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 10
Open Access | Times Cited: 58
ACSL4-Mediated Ferroptosis and Its Potential Role in Central Nervous System Diseases and Injuries
Bowen Jia, Jing Li, Yiting Song, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10021-10021
Open Access | Times Cited: 43
Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases
Qian Huang, Yi Ru, Ying‐Li Luo, et al.
Science Advances (2024) Vol. 10, Iss. 13
Open Access | Times Cited: 35
ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression
Julia Grube, Marius Maximilian Woitok, Antje Mohs, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 8
Open Access | Times Cited: 58
ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics
Jun Hou, Changqing Jiang, Xudong Wen, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 50
Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis
Xiaoying Jiang, Kaiyu Wu, Xiang‐Yang Ye, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 4, pp. 872-896
Closed Access | Times Cited: 30
Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease
Yue Dai, Yuting Chen, Dexiameng Mo, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 25
Inhibition of CARM1‐Mediated Methylation of ACSL4 Promotes Ferroptosis in Colorectal Cancer
Shengjie Feng, Zejun Rao, Jiakun Zhang, et al.
Advanced Science (2023) Vol. 10, Iss. 36
Open Access | Times Cited: 23
Characterization of ferroptosis-triggered pyroptotic signaling in heart failure
Xukun Bi, Xiaotian Wu, Jiaqi Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 12
Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells
W. Wang, Tongtong Wang, YAN ZHANG, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 3, pp. 489-502
Open Access | Times Cited: 10
ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization
Yuqi Wang, Mangze Hu, Jian Cao, et al.
Cell (2024)
Closed Access | Times Cited: 9
SLC35C2 promotes stemness and progression in hepatocellular carcinoma by activating lipogenesis
Chunhui Qi, Bin Cao, Zhiwen Gong, et al.
Cellular Signalling (2025) Vol. 127, pp. 111589-111589
Closed Access | Times Cited: 1
The lipid metabolism remodeling: A hurdle in breast cancer therapy
Qian Xiao, Min Xia, Weijian Tang, et al.
Cancer Letters (2023) Vol. 582, pp. 216512-216512
Closed Access | Times Cited: 17
ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription
Dandan Wu, Zongchao Zuo, Xinning Sun, et al.
Biochemical Pharmacology (2024) Vol. 224, pp. 116206-116206
Closed Access | Times Cited: 8
Ferroptosis in age-related vascular diseases: Molecular mechanisms and innovative therapeutic strategies
Yue Dai, Xiuxian Wei, Tao Jiang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116356-116356
Open Access | Times Cited: 6
ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin
Guoliang Dai, Dong Wang, Shitang Ma, et al.
Phytomedicine (2022) Vol. 102, pp. 154149-154149
Closed Access | Times Cited: 27
The Physiological and Pathological Role of Acyl-CoA Oxidation
Sylwia Szrok-Jurga, Aleksandra Czumaj, Jacek Turyn, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14857-14857
Open Access | Times Cited: 16
ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis
Jiasi Zhang, Yuxi Liu, Qun Li, et al.
Carcinogenesis (2023) Vol. 44, Iss. 3, pp. 242-251
Closed Access | Times Cited: 15
Targeting ACSLs to modulate ferroptosis and cancer immunity
Junhong Lin, Yongfeng Lai, Fujia Lu, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 5
Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
Chuncao Xu, Lei Zhang, Daifei Wang, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top